Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9777486 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL4863423 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL7939387 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL7568412 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL10430031 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL29030882 | 0.76 | IDO1 (0.54) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL19284235 | 0.76 | IDO1 (0.54) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL19299713 | 0.75 | MEN1 (0.52) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL28582529 | 0.75 | MAOB (0.59) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL2563361 | 0.75 | MAOB (0.59) | IDO1PAMMAOBHTR2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106471015-A | Graft polymer, resin colored product, method for producing resin colored product, and resin composition containing resin colored product | 和光纯药工业株式会社 | 2017-03-01 | — | — | CN | disclosed |
| CN-103038701-B | Polymer-stabilized thermotropic liquid crystal device | 雷文布里克有限责任公司 | 2017-01-18 | — | — | CN | disclosed |
| US-8367792-B2 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208973-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | OOTAKE NOBUMASA (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8173758-B2 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110178313-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | OOTAKE NOBUMASA | 2011-07-21 | — | — | US | disclosed |
| US-7939617-B2 | Silsesquioxane derivative; electronic material, optical material, optoelectronic material, paint, and primer. | CHISSO CORPORATION (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20080171846-A1 | Polysiloxane compound and method of producing the same | JNC CORPORATION (JP) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178313-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | RPS4X, POLR2A, MSL1 | IDO1 4256/4885PAM 1229/4885MAOB 3934/4885 |
| US-20120208973-A1 | POLYSILOXANE COMPOUND AND METHOD OF PRODUCING THE SAME | RPS4X, POLR2A, MSL1 | IDO1 4256/4885PAM 1229/4885MAOB 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.